BRIEF published on 08/01/2025 at 14:05, 4 months 3 days ago CARMAT: Resumption of Quotation and Update on Judicial Recovery Takeover Offer CARMAT Resumption Of Quotation Judicial Recovery Aeson® Artificial Heart
BRIEF published on 07/01/2025 at 20:50, 5 months 3 days ago Half-yearly report on CARMAT's liquidity contract Liquidity Contract Actions CARMAT Judicial Recovery Stockbroker
BRIEF published on 06/20/2025 at 19:15, 5 months 14 days ago CARMAT launches a donation campaign in the face of a financial crisis Funding Heart Failure Artificial Heart Financial Crisis Donation Campaign
PRESS RELEASE published on 06/20/2025 at 19:10, 5 months 14 days ago Inside Information / Other news releases CARMAT launches a donation campaign to address critical financial situation and risk of insolvency. The initiative aims to secure urgent funding for its innovative total artificial heart Financial Situation CARMAT Artificial Heart Donation Campaign Risk Of Insolvency
BRIEF published on 06/04/2025 at 17:50, 6 months ago CARMAT: Terms and conditions for the General Meeting of June 26, 2025 General Assembly Remote Voting CARMAT Artificial Heart Financial Risks
BRIEF published on 06/02/2025 at 07:05, 6 months 2 days ago CARMAT makes its first sales of artificial hearts in Israel CARMAT European Union Israel Aeson® Locations
BRIEF published on 04/09/2025 at 17:50, 7 months 25 days ago CARMAT Achieves Strong Q1 2025 Results CARMAT Q1 2025 FDA Discussions Aeson® Implants EFICAS Trial
PRESS RELEASE published on 04/09/2025 at 17:45, 7 months 25 days ago Inside Information / Other news releases CARMAT delivers strong Q1 2025 results with €2.4m sales, progresses EFICAS trial, and advances FDA discussions for EFS study in the US. Aiming for long-term patient support with enhanced heart by end of 2025 CARMAT Long-term Support FDA Discussions Q1 2025 Results EFICAS Trial
BRIEF published on 02/17/2025 at 07:05, 9 months 15 days ago CARMAT's Aeson® Artificial Heart: Promising Results for Heart Failure with Pulmonary Hypertension Medical Innovation Heart Failure Treatment Aeson® Artificial Heart Pulmonary Hypertension Transplant Eligibility
PRESS RELEASE published on 02/17/2025 at 07:00, 9 months 15 days ago Inside Information / Other news releases CARMAT's Aeson® total artificial heart, featured in The Journal of Heart and Lung Transplantation, offers a promising solution for heart failure patients with pulmonary hypertension, potentially becoming a standard treatment Heart Failure CARMAT Aeson® Pulmonary Hypertension Transplant
Published on 12/05/2025 at 02:35, 3 hours 52 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 27 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 22 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 27 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 36 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 12 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 12 hours 27 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 42 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 26 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago Declaration of voting rights at the end of November 2025
